Average Price Target: A$0.00
This price target is based on 0 analysts offering 12 month price targets for Cochlear in the last 3 months. The average price target is A$0.00, with a high forecast of A$0.00 and a low forecast of A$10,000,000.00. The average price target represents a NaN upside from the last price of A$0.00.
The current consensus among 0 polled investment analysts is to n/a stock in Cochlear. This rating has held steady since November 2019, when it changed from a Buy consensus rating.
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7, Nucleus 6, Nucleus CP802, and Kanso sound processors; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, and Baha sound processor. It also provides Cochlear true wireless accessories comprising mini microphones, phone clips, and TV streamers; Nucleus water-safe accessories; and training and development services. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.